High-dose methylprednisolone is effective in the management of acute graft-versus-host disease in severe combined immune deficiency
To the Editor: Severe combined immune deficiency (SCID) is a heterogeneous group of inherited diseases characterized by significantly impaired immunity leading to death in infancy unless treated with bone marrow transplantation (BMT).1 When successful, BMT provides full immune reconstitution and lon...
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology 2008-12, Vol.122 (6), p.1215-1216 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1216 |
|---|---|
| container_issue | 6 |
| container_start_page | 1215 |
| container_title | Journal of allergy and clinical immunology |
| container_volume | 122 |
| creator | Somech, Raz, MD Kavadas, Fotini D., MD Atkinson, Adelle, MD Grunebaum, Eyal, MD Roifman, Chaim M., MD, FRCPC |
| description | To the Editor: Severe combined immune deficiency (SCID) is a heterogeneous group of inherited diseases characterized by significantly impaired immunity leading to death in infancy unless treated with bone marrow transplantation (BMT).1 When successful, BMT provides full immune reconstitution and long-term survival. Typical first-line treatment includes a regimen of 2 mg/kg/d MP.7 However, a prospective study on MP doses of 2 mg/kg/d failed to show a significant advantage of this dose regimen.8 In contrast, the use of higher doses of 20 mg/kg showed a 43% response rate in aGvHD.9 We studied the use of high-dose MP pulse in patients with SCID after matched unrelated donor BMT who had aGvHD of grade II or higher, which emerged in spite of aGvHD prophylaxis and was not tamed by standard 2 mg/kg MP. Sixteen patients who developed aGvHD after receiving MUD BMT for SCID between 1996 and 2006 were included in this study (Table I). |
| doi_str_mv | 10.1016/j.jaci.2008.06.023 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69901542</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091674908011718</els_id><sourcerecordid>19517984</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-d89184e166e33d5f4cebab49f7015aa52fde18d3335d9ff36bead8889eac65da3</originalsourceid><addsrcrecordid>eNqFktGL1DAQxoMo3nr6D_ggAcG31qRp0wREOA69OzjwQX0OaTLZTW2bNWkX9tl_3PR24eAe9GkY5vd9MPMNQm8pKSmh_GNf9tr4siJElISXpGLP0IYS2RZcVM1ztCFE0oK3tbxAr1LqSe6ZkC_RBRW8rapWbtCfW7_dFTYkwCPMu-Owj2Ann8IQJsA-YXAOzOwPuZnwvMuYnvQWRphmHBzWZpkBb6N2c3GAmJZU7EKasfUJdHoQJcgDwCaMnZ_AYj-OS_a24LzxMJnja_TC6SHBm3O9RD-_fvlxfVvcf7u5u766L0zNxVxYIamogXIOjNnG1QY63dXStYQ2WjeVs0CFZYw1VjrHeAfaCiEkaMMbq9kl-nDy3cfwe4E0q9EnA8OgJwhLUlzK7FRX_wWpbGgrRZ3B90_APixxykso2pBaEMmZzFR1okwMKUVwah_9qONRUaLWJFWv1iTVmqQiXOUks-jd2XrpRrCPknN0Gfh0AiCf7OAhqvRwTrA-5sSUDf7f_p-fyM3gJ2_08AuOkB73UKlSRH1ff2l9JSIIpS0V7C-huca0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504809639</pqid></control><display><type>article</type><title>High-dose methylprednisolone is effective in the management of acute graft-versus-host disease in severe combined immune deficiency</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Somech, Raz, MD ; Kavadas, Fotini D., MD ; Atkinson, Adelle, MD ; Grunebaum, Eyal, MD ; Roifman, Chaim M., MD, FRCPC</creator><creatorcontrib>Somech, Raz, MD ; Kavadas, Fotini D., MD ; Atkinson, Adelle, MD ; Grunebaum, Eyal, MD ; Roifman, Chaim M., MD, FRCPC</creatorcontrib><description>To the Editor: Severe combined immune deficiency (SCID) is a heterogeneous group of inherited diseases characterized by significantly impaired immunity leading to death in infancy unless treated with bone marrow transplantation (BMT).1 When successful, BMT provides full immune reconstitution and long-term survival. Typical first-line treatment includes a regimen of 2 mg/kg/d MP.7 However, a prospective study on MP doses of 2 mg/kg/d failed to show a significant advantage of this dose regimen.8 In contrast, the use of higher doses of 20 mg/kg showed a 43% response rate in aGvHD.9 We studied the use of high-dose MP pulse in patients with SCID after matched unrelated donor BMT who had aGvHD of grade II or higher, which emerged in spite of aGvHD prophylaxis and was not tamed by standard 2 mg/kg MP. Sixteen patients who developed aGvHD after receiving MUD BMT for SCID between 1996 and 2006 were included in this study (Table I).</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2008.06.023</identifier><identifier>PMID: 18672279</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>Acute Disease ; Age ; Allergy and Immunology ; Anti-Inflammatory Agents - administration & dosage ; Blood pressure ; Bone marrow ; Bone Marrow Transplantation ; Disease-Free Survival ; Female ; Graft vs Host Disease - drug therapy ; Graft vs Host Disease - genetics ; Graft vs Host Disease - mortality ; Humans ; Infant ; Infant, Newborn ; Male ; Medical treatment ; Methylprednisolone - administration & dosage ; Patients ; Retrospective Studies ; Severe Combined Immunodeficiency - genetics ; Severe Combined Immunodeficiency - mortality ; Severe Combined Immunodeficiency - therapy ; Transplants & implants</subject><ispartof>Journal of allergy and clinical immunology, 2008-12, Vol.122 (6), p.1215-1216</ispartof><rights>American Academy of Allergy, Asthma & Immunology</rights><rights>2008 American Academy of Allergy, Asthma & Immunology</rights><rights>Copyright Elsevier Limited Dec 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-d89184e166e33d5f4cebab49f7015aa52fde18d3335d9ff36bead8889eac65da3</citedby><cites>FETCH-LOGICAL-c468t-d89184e166e33d5f4cebab49f7015aa52fde18d3335d9ff36bead8889eac65da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0091674908011718$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18672279$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Somech, Raz, MD</creatorcontrib><creatorcontrib>Kavadas, Fotini D., MD</creatorcontrib><creatorcontrib>Atkinson, Adelle, MD</creatorcontrib><creatorcontrib>Grunebaum, Eyal, MD</creatorcontrib><creatorcontrib>Roifman, Chaim M., MD, FRCPC</creatorcontrib><title>High-dose methylprednisolone is effective in the management of acute graft-versus-host disease in severe combined immune deficiency</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>To the Editor: Severe combined immune deficiency (SCID) is a heterogeneous group of inherited diseases characterized by significantly impaired immunity leading to death in infancy unless treated with bone marrow transplantation (BMT).1 When successful, BMT provides full immune reconstitution and long-term survival. Typical first-line treatment includes a regimen of 2 mg/kg/d MP.7 However, a prospective study on MP doses of 2 mg/kg/d failed to show a significant advantage of this dose regimen.8 In contrast, the use of higher doses of 20 mg/kg showed a 43% response rate in aGvHD.9 We studied the use of high-dose MP pulse in patients with SCID after matched unrelated donor BMT who had aGvHD of grade II or higher, which emerged in spite of aGvHD prophylaxis and was not tamed by standard 2 mg/kg MP. Sixteen patients who developed aGvHD after receiving MUD BMT for SCID between 1996 and 2006 were included in this study (Table I).</description><subject>Acute Disease</subject><subject>Age</subject><subject>Allergy and Immunology</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Blood pressure</subject><subject>Bone marrow</subject><subject>Bone Marrow Transplantation</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Graft vs Host Disease - drug therapy</subject><subject>Graft vs Host Disease - genetics</subject><subject>Graft vs Host Disease - mortality</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Methylprednisolone - administration & dosage</subject><subject>Patients</subject><subject>Retrospective Studies</subject><subject>Severe Combined Immunodeficiency - genetics</subject><subject>Severe Combined Immunodeficiency - mortality</subject><subject>Severe Combined Immunodeficiency - therapy</subject><subject>Transplants & implants</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFktGL1DAQxoMo3nr6D_ggAcG31qRp0wREOA69OzjwQX0OaTLZTW2bNWkX9tl_3PR24eAe9GkY5vd9MPMNQm8pKSmh_GNf9tr4siJElISXpGLP0IYS2RZcVM1ztCFE0oK3tbxAr1LqSe6ZkC_RBRW8rapWbtCfW7_dFTYkwCPMu-Owj2Ann8IQJsA-YXAOzOwPuZnwvMuYnvQWRphmHBzWZpkBb6N2c3GAmJZU7EKasfUJdHoQJcgDwCaMnZ_AYj-OS_a24LzxMJnja_TC6SHBm3O9RD-_fvlxfVvcf7u5u766L0zNxVxYIamogXIOjNnG1QY63dXStYQ2WjeVs0CFZYw1VjrHeAfaCiEkaMMbq9kl-nDy3cfwe4E0q9EnA8OgJwhLUlzK7FRX_wWpbGgrRZ3B90_APixxykso2pBaEMmZzFR1okwMKUVwah_9qONRUaLWJFWv1iTVmqQiXOUks-jd2XrpRrCPknN0Gfh0AiCf7OAhqvRwTrA-5sSUDf7f_p-fyM3gJ2_08AuOkB73UKlSRH1ff2l9JSIIpS0V7C-huca0</recordid><startdate>20081201</startdate><enddate>20081201</enddate><creator>Somech, Raz, MD</creator><creator>Kavadas, Fotini D., MD</creator><creator>Atkinson, Adelle, MD</creator><creator>Grunebaum, Eyal, MD</creator><creator>Roifman, Chaim M., MD, FRCPC</creator><general>Mosby, Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20081201</creationdate><title>High-dose methylprednisolone is effective in the management of acute graft-versus-host disease in severe combined immune deficiency</title><author>Somech, Raz, MD ; Kavadas, Fotini D., MD ; Atkinson, Adelle, MD ; Grunebaum, Eyal, MD ; Roifman, Chaim M., MD, FRCPC</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-d89184e166e33d5f4cebab49f7015aa52fde18d3335d9ff36bead8889eac65da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acute Disease</topic><topic>Age</topic><topic>Allergy and Immunology</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Blood pressure</topic><topic>Bone marrow</topic><topic>Bone Marrow Transplantation</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Graft vs Host Disease - drug therapy</topic><topic>Graft vs Host Disease - genetics</topic><topic>Graft vs Host Disease - mortality</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Methylprednisolone - administration & dosage</topic><topic>Patients</topic><topic>Retrospective Studies</topic><topic>Severe Combined Immunodeficiency - genetics</topic><topic>Severe Combined Immunodeficiency - mortality</topic><topic>Severe Combined Immunodeficiency - therapy</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Somech, Raz, MD</creatorcontrib><creatorcontrib>Kavadas, Fotini D., MD</creatorcontrib><creatorcontrib>Atkinson, Adelle, MD</creatorcontrib><creatorcontrib>Grunebaum, Eyal, MD</creatorcontrib><creatorcontrib>Roifman, Chaim M., MD, FRCPC</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Somech, Raz, MD</au><au>Kavadas, Fotini D., MD</au><au>Atkinson, Adelle, MD</au><au>Grunebaum, Eyal, MD</au><au>Roifman, Chaim M., MD, FRCPC</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High-dose methylprednisolone is effective in the management of acute graft-versus-host disease in severe combined immune deficiency</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>2008-12-01</date><risdate>2008</risdate><volume>122</volume><issue>6</issue><spage>1215</spage><epage>1216</epage><pages>1215-1216</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><abstract>To the Editor: Severe combined immune deficiency (SCID) is a heterogeneous group of inherited diseases characterized by significantly impaired immunity leading to death in infancy unless treated with bone marrow transplantation (BMT).1 When successful, BMT provides full immune reconstitution and long-term survival. Typical first-line treatment includes a regimen of 2 mg/kg/d MP.7 However, a prospective study on MP doses of 2 mg/kg/d failed to show a significant advantage of this dose regimen.8 In contrast, the use of higher doses of 20 mg/kg showed a 43% response rate in aGvHD.9 We studied the use of high-dose MP pulse in patients with SCID after matched unrelated donor BMT who had aGvHD of grade II or higher, which emerged in spite of aGvHD prophylaxis and was not tamed by standard 2 mg/kg MP. Sixteen patients who developed aGvHD after receiving MUD BMT for SCID between 1996 and 2006 were included in this study (Table I).</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>18672279</pmid><doi>10.1016/j.jaci.2008.06.023</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of allergy and clinical immunology, 2008-12, Vol.122 (6), p.1215-1216 |
| issn | 0091-6749 1097-6825 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69901542 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Acute Disease Age Allergy and Immunology Anti-Inflammatory Agents - administration & dosage Blood pressure Bone marrow Bone Marrow Transplantation Disease-Free Survival Female Graft vs Host Disease - drug therapy Graft vs Host Disease - genetics Graft vs Host Disease - mortality Humans Infant Infant, Newborn Male Medical treatment Methylprednisolone - administration & dosage Patients Retrospective Studies Severe Combined Immunodeficiency - genetics Severe Combined Immunodeficiency - mortality Severe Combined Immunodeficiency - therapy Transplants & implants |
| title | High-dose methylprednisolone is effective in the management of acute graft-versus-host disease in severe combined immune deficiency |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T13%3A23%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High-dose%20methylprednisolone%20is%20effective%20in%20the%20management%20of%20acute%20graft-versus-host%20disease%20in%20severe%20combined%20immune%20deficiency&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Somech,%20Raz,%20MD&rft.date=2008-12-01&rft.volume=122&rft.issue=6&rft.spage=1215&rft.epage=1216&rft.pages=1215-1216&rft.issn=0091-6749&rft.eissn=1097-6825&rft_id=info:doi/10.1016/j.jaci.2008.06.023&rft_dat=%3Cproquest_cross%3E19517984%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1504809639&rft_id=info:pmid/18672279&rft_els_id=S0091674908011718&rfr_iscdi=true |